1. Executive Summary (Confidence: High)

Araris Biotech has positioned itself as a transformative force within the oncology and longevity sectors by resolving the fundamental stability and manufacturing constraints that have historically plagued antibody-drug conjugates (ADCs). Founded as a spin-off from the Paul Scherrer Institute (PSI) and ETH Zurich, the company’s trajectory culminated in a landmark acquisition by Taiho Pharmaceutical Co., Ltd. in March 2025.^[1] This acquisition underscores the strategic value of Araris's AraLinQ™ technology, which facilitates the attachment of multiple, synergistic payloads to "off-the-shelf" antibodies in a single enzymatic step.^[1] By achieving high levels of drug-to-antibody ratio (DAR) uniformity and exceptional linker stability, Araris provides a pathway toward therapies that minimize systemic toxicity while maximizing anti-tumor efficacy. The company’s commercial validation is further evidenced by a $780 million licensing agreement with Chugai Pharmaceutical and a research collaboration with Johnson & Johnson, establishing it as a critical node in the global biopharmaceutical infrastructure.^[2]